Related references
Note: Only part of the references are listed.Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
Saad Z. Usmani et al.
BLOOD (2013)
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
E. Kastritis et al.
LEUKEMIA (2013)
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
Brian A. Walker et al.
BLOOD (2012)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
Jan B. Egan et al.
BLOOD (2012)
Myeloma as a model for the process of metastasis: implications for therapy
Irene M. Ghobrial
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2012)
Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma
Jens Hillengass et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Approach to the treatment of multiple myeloma: a clash of philosophies
S. Vincent Rajkumar et al.
BLOOD (2011)
The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells
Lucia Lopez-Corral et al.
CLINICAL CANCER RESEARCH (2011)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Bart Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R. A. Kyle et al.
LEUKEMIA (2010)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla B. Bartel et al.
BLOOD (2009)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri et al.
BLOOD (2008)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona et al.
BLOOD (2007)
Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications
Ronald Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
